Platform
Company
Immunology & Autoimmune
Review status
Currently under review
Pending specialist review and validation.
The Anti-Jo-1 antibody test measures autoantibodies that target histidyl tRNA synthetase, a protein involved in building new proteins inside cells. These antibodies are part of the myositis-specific autoantibody group and are most strongly linked with a condition called antisynthetase syndrome.
Your clinician may order this test when evaluating symptoms such as muscle weakness, joint pain, or breathing difficulties that could be related to autoimmune muscle disease. It is often performed alongside other myositis antibodies and tests of muscle inflammation to build a clearer picture of what is going on.
Finding Anti-Jo-1 antibodies can help support a diagnosis of antisynthetase syndrome or idiopathic inflammatory myopathy, conditions that can affect muscles, lungs, and joints. A positive result may point toward a pattern of disease that includes muscle inflammation and a risk for interstitial lung involvement, which can influence monitoring and treatment decisions.
This test is commonly ordered when there is concern for autoimmune myositis, especially if you have muscle weakness, elevated muscle enzymes, joint symptoms, or respiratory complaints. Results help your care team decide on additional testing, referrals to rheumatology or pulmonology, and whether to begin or adjust immunosuppressive therapy.
A positive Anti-Jo-1 result increases the likelihood of antisynthetase syndrome or autoimmune myositis, but it does not confirm a diagnosis by itself. Some people with these antibodies have mainly lung or joint symptoms, and the antibody can persist even when symptoms improve. Your clinician will interpret the result together with your history, exam, muscle enzymes, imaging, and pulmonary testing.
A negative result does not rule out autoimmune myositis, since other myositis-specific antibodies may be involved. If your symptoms continue, your clinician may order a broader myositis panel, repeat testing with a different method, or pursue imaging, electromyography, or tissue biopsy. Discuss any new or worsening shortness of breath or muscle weakness promptly, since early evaluation can improve outcomes.
Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.
Different assays (ELISA, line blot, chemiluminescent) can yield slightly different results. Reference intervals and cutoffs are method specific, so comparisons across labs are not always direct.
Treatments such as corticosteroids, rituximab, or other immunosuppressants may lower detectable antibody levels or change trends over time, which can affect interpretation.
Intravenous immunoglobulin and some blood products can transiently introduce or mask autoantibodies, potentially leading to unexpected positive or negative results.
People with other autoimmune diseases can have overlapping antibodies, and occasional low-level reactivity may not reflect active muscle or lung disease.
Anti-Jo-1 may remain detectable even when symptoms improve, and levels do not always track day-to-day disease activity. Your clinician will focus on the clinical picture.
Improper sample handling, severe hemolysis, or prolonged storage can affect some immunoassays. Using a properly collected and promptly processed serum sample helps reliability.
Smoking and other lung irritants can worsen respiratory symptoms in antisynthetase syndrome, which may prompt more intensive evaluation if Anti-Jo-1 is present.
Immune changes in pregnancy and early life can alter autoantibody profiles. Test interpretation should be individualized in these settings.
References